Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDOSafe: Hormonal Therapies for Post-Surgical Endometriosis
NCT06145438Phase 3Completed
- Sponsor
- Diponegoro University
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dienogest in endometriosis (4 arms), sponsored by Diponegoro University. Primary endpoints: Beta estradiol level at 12 weeks and TNF alpha level at 12 weeks. Started Sep 2023; status: completed.
02
Drugs
dienogest
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT06145438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145438.